Gerak LR[au] - Search Results

Year	Number of Results
1994	3
1995	1
1996	2
1997	3
1998	5
1999	4
2000	1
2001	2
2002	1
2003	1
2004	2
2005	1
2006	3
2007	2
2008	5
2009	3
2010	3
2011	5
2012	2
2013	6
2014	3
2015	3
2016	6
2017	2
2018	5
2019	6
2020	5
2021	2
2022	3
2023	0

1

Countermeasures for Preventing and Treating Opioid Overdose.

France CP, Ahern GP, Averick S, Disney A, Enright HA, Esmaeli-Azad B, Federico A, Gerak LR, Husbands SM, Kolber B, Lau EY, Lao V, Maguire DR, Malfatti MA, Martinez G, Mayer BP, Pravetoni M, Sahibzada N, Skolnick P, Snyder EY, Tomycz N, Valdez CA, Zapf J. France CP, et al. Among authors: gerak lr. Clin Pharmacol Ther. 2021 Mar;109(3):578-590. doi: 10.1002/cpt.2098. Epub 2020 Nov 29. Clin Pharmacol Ther. 2021. PMID: 33113208 Free PMC article. Review.

2

Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors.

Gerak LR, Maguire DR, France CP. Gerak LR, et al. Handb Exp Pharmacol. 2020;258:127-145. doi: 10.1007/164_2019_265. Handb Exp Pharmacol. 2020. PMID: 31451969 Review.

3

The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders.

Collins GT, Gerak LR, France CP. Collins GT, et al. Among authors: gerak lr. Neuropharmacology. 2018 Nov;142:63-71. doi: 10.1016/j.neuropharm.2017.12.023. Epub 2017 Dec 12. Neuropharmacology. 2018. PMID: 29246856 Free PMC article. Review.

4

OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects.

Gerak LR, Maguire DR, Cami-Kobeci G, Olson KM, Traynor JR, Husbands SM, France CP, Acevedo L, Belli B, Flynn P. Gerak LR, et al. Behav Pharmacol. 2022 Sep 1;33(6):377-394. doi: 10.1097/FBP.0000000000000684. Epub 2022 Aug 3. Behav Pharmacol. 2022. PMID: 35947066

5

Preclinical Assessment of the Abuse Potential of Purified Botanical Cannabidiol: Self-Administration, Drug Discrimination, and Physical Dependence.

Gray RA, Heal DJ, Maguire DR, Gerak LR, Javors MA, Smith S, France CP. Gray RA, et al. Among authors: gerak lr. J Pharmacol Exp Ther. 2022 Jul;382(1):54-65. doi: 10.1124/jpet.121.000988. Epub 2022 Apr 30. J Pharmacol Exp Ther. 2022. PMID: 35489780

6

Attenuation of the positive-reinforcing effects of ultra-potent fentanyl analogs, along with those of fentanyl and heroin, during daily treatment with methocinnamox (MCAM) in rhesus monkeys.

Gerak LR, France CP. Gerak LR, et al. J Pharmacol Exp Ther. 2022 Dec 27:JPET-AR-2022-001267. doi: 10.1124/jpet.122.001267. Online ahead of print. J Pharmacol Exp Ther. 2022. PMID: 36575032 Free article.

7

Cross-tolerance to cannabinoids in morphine-tolerant rhesus monkeys.

Gerak LR, Zanettini C, Koek W, France CP. Gerak LR, et al. Psychopharmacology (Berl). 2015 Oct;232(19):3637-47. doi: 10.1007/s00213-015-4023-x. Epub 2015 Jul 23. Psychopharmacology (Berl). 2015. PMID: 26202613

8

Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys.

Maguire DR, Gerak LR, Woods JH, Husbands SM, Disney A, France CP. Maguire DR, et al. Among authors: gerak lr. J Pharmacol Exp Ther. 2019 Jan;368(1):88-99. doi: 10.1124/jpet.118.252353. Epub 2018 Nov 6. J Pharmacol Exp Ther. 2019. PMID: 30401680

9

OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention.

Maguire DR, Gerak LR, Cami-Kobeci G, Husbands SM, France CP, Belli B, Flynn P. Maguire DR, et al. Among authors: gerak lr. J Pharmacol Exp Ther. 2020 Feb;372(2):205-215. doi: 10.1124/jpet.119.261511. Epub 2019 Nov 20. J Pharmacol Exp Ther. 2020. PMID: 31748404 Free PMC article.

10

Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys.

Weed PF, Gerak LR, France CP. Weed PF, et al. Among authors: gerak lr. Eur J Pharmacol. 2018 Aug 15;833:94-99. doi: 10.1016/j.ejphar.2018.05.041. Epub 2018 May 26. Eur J Pharmacol. 2018. PMID: 29807027 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results